期刊
ANNALS OF ONCOLOGY
卷 27, 期 10, 页码 1966-1969出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdw288
关键词
-
类别
The role of tumor PD-L1 expression was investigated across the nivolumab clinical development program. Phase III nivolumab trials have shown that patients with tumors not expressing PD-L1 may benefit; therefore, testing is not required to select patients for therapy. The Dako PD-L1 IHC 28-8 pharmDx assay may be used to determine tumor PD-L1 expression as a complementary and informative test.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据